FCF Healthcare & Life Sciences
Venture Capital Monitor
-
Europe

The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Healthcare & Life Sciences industry.

FCF Healthcare & Life Sciences Venture Capital Monitor - Europe

As of the end of October 2024 we identified the following current VC trends in Europe:

  • Total Healthcare & Life Sciences funding reached EUR 31,125m
  • Biotech/Pharma received 54% of the total investment volume (EUR 16,712m) with oncology being the leading indication (28%)
  • In October Treeline Biosciences secured the highest transaction volume with EUR 381m, followed by Kailera Therapeutics with EUR 360m and Alpha-9 Oncology with EUR 159m
  • RA Capital Management (United States) is the most active investor (by deal volume in 2024), followed by ARCH Venture Partners (United States) and Atlas Venture (United States)
FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous slide
Next slide
To receive a copy please click here

Capital Markets Research

Monthly Venture capital activities in the European Life Sciences sector
Click Here
Healthcare & Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the US Life Sciences sector
Click here
Healthcare & Life Sciences Venture Capital Monitor – USA
Monthly Venture capital activities in the European Life Sciences sector
Click Here
Healthcare & Life Sciences Venture Capital Monitor – Europe
Recent valuations of listed US Life Sciences companies
Click here
Healthcare & Life Sciences Venture Capital Monitor – USA

Healthcare & Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector

Healthcare & Life Sciences Venture Capital Monitor – USA
Monthly Venture capital activities in the US Life Sciences sector

NEWS

more...